Karyopharm Therapeutics reported $-51706000 in Pre-Tax Profit for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Abbott ABT:US $ 2982M 513M
Acceleron Pharma XLRN:US $ -70.45M 6.94M
AstraZeneca AZN:LN 1954M 415M
Bristol Myers Squibb BMY:US $ 5289M 67M
Eli Lilly And LLY:US $ 1470.5M 518.1M
Enanta Pharmaceuticals ENTA:US $ -33.39M 0.01M
Epizyme EPZM:US $ -65.83M 1.47M
Five Prime Therapeutics FPRX:US $ -20.85M 0M
Johnson & Johnson JNJ:US $ 8058M 282M
Karyopharm Therapeutics KPTI:US $ -51706000 1.74M
Macrogenics MGNX:US $ -52.89M 12.95M
Mirati Therapeutics MRTX:US $ -76.76M 89.68M
Nektar Therapeutics NKTR:US $ -129.59M 4.43M
Novartis NOVN:VX SF 4544M 120M
Novartis NVS:US $ 4544M 120M
Regeneron Pharmaceuticals REGN:US $ 1822.2M 2076.1M
Sangamo Biosciences SGMO:US $ -47.6M 0.45M
Takeda 4502:JP Y 61447M 161531M
Tg Therapeutics TGTX:US $ -85.64M 7.14M
Ultragenyx Pharmaceutical RARE:US $ -72.82M 49.15M
Xencor XNCR:US $ -40.19M 92.44M